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ABSTRACT  
The aim of the study was to increase the aqueous solubility, dissolution rate, stability, in vitro anti-
tubercular activity and bioavailability of rifampicin by the way of inclusion complexation. Methyl β-
cyclodextrin in case of rifampicin were used. Based on phase solubility studies that stoichiometry 
of complex of with respect to β-cyclodextrin for rifampicin was found to be 1:1 molar ratio. 
Different methods of preparation such as kneading and common solvent were employed to 
prepare the complexes. Formation of complexes In case of rifampicin, interaction of 4-methyl 
piperazin-1-ylimino-methyl (side chain) of rifampicin with the cyclodextrin molecule was 
confirmed by FTIR and 1H-NMR. The complexes prepared by different methods were subjected to 
solubility and in vitro dissolution studies. In case of rifampicin, in vitro anti-tubercular activity was 
found to be enhanced for the complexes of rifampicin indicated by a reduction in MIC of rifampicin. 
The oral bioavailability of rifampicin-Mβ-CD complex prepared by common solvent method was 
improved significantly. The results of stability studies revealed that stability of the drugs in 
solution and solid state were improved significantly due to complexation. Photostability of 
rifampicin is enhanced significantly by the way of complexation. Thus inclusion complexation of 
rifampicin with β-cyclodextrin, β-cyclodextrin derivatives and γ-cyclodextrin improved its physical 
properties, bioavailability and in vitro activity. 
KEYWORDS: Rifampicin, β-cyclodextrin derivatives, γ-cyclodextrin, Dissolution, Characterization, 
Bioavailability, Thermal Stability, Photostability, in vitro anti-tubercular activity.  
INTRODUCTION 
Pyrazinamide (Pyr) and rifampicin (Rif) are 
two of the first-line anti-tubercular drugs. They are 
poorly soluble in water. It is known to cause serious 
side effects such as hepatotoxicity, anorexia, nausea, 
vomiting and dysuria. The treatment for tuberculosis 
requires long time therapy, which may aggravate 
gastric adverse effects. Rif is prone to acid hydrolysis 
giving rise to 3-formylrifampicin SV where the side 
chain i.e. 4-methyl piperazin-1-ylimino-methyl is 
detached. Rifampicin is also prone to air oxidation of 
the paraphenolic groups in the naphthalene ring to give 
the p-quinone. It was reported that its oral absorption 
is decreased when side chain, 4-methyl piperazin-1-
ylimino-methyl is detached. The mechanism of 
antibacterial action of rifampicin is inhibition of the 
activity of the enzyme DNA-directed RNA polymerase 
(DDRP). Although the main mechanism of resistance is 
the modification of the target enzyme, some mutagenic 
treatments yield resistant mutants in which the RNA 
polymerase is still highly sensitive to the drug, but the 
rate of rifampicin uptake is reduced. The mechanism of 
this permeability mutation is not yet clear. 6 Any 
attempt to increase the permeability would be 
advantageous in the treatment of resistant mutant. 
Cyclodextrin (CD) has been reported to increase 
permeability. Main adverse effects of rifampicin are flu-
like syndrome and cutaneous syndrome, nausea 
vomiting, aneroxia, diarrhoea and epigastric distress. 
Thus it was felt that there is a need to reduce the 
gastric distress, increase the uptake of rifampicin in 
order to reduce the MIC, increase the stability and 
improve bioavailability. 
Material and methods 
β-CD (HiMedia Laboratories Pvt Limited, 
Mumbai, India) and all other chemicals used were 
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A.R.Grade (Merck, Limited, Mumbai, India).β-CD 
derivatives that is methyl-β-CD were obtained as gift 
sample. Rifampicin was obtained as gift sample from 
KAPL, Bangalore, India. All the chemicals (Sigma 
Aldrich Chemie Gmbh, Steinheim, Germany) were 
purchased for the preparation of Lowenstein-Jensen 
medium (L.J. medium). HPLC grade water (Merck 
Limited, Mumbai, India) and acetonitrile (Qualigens 
Fine chemicals, Mumbai) were purchased. 
Dichloromethane and diethyl ether are analytical grade 
were freshly distilled before use; hydrochloric acid; 
water was HPLC grade (Merck Limited, Mumbai, India), 
acetonitrile (Qualigens Fine chemicals, Mumbai) and 
paracetamol. 
Phase Solubility: Phase solubility studies were carried 
by taking excess of rifampicin is added to 10 ml of an 
aqueous solution of β-CD ranging from 5 mM to 15 mM 
and different concentrations 100mM of β-CD 
derivatives in a series of 25 mL stoppered conical flasks 
and the mixtures were shaken for 48 hours at room 
temperature on a rotary flask shaker. After 48 hours 
shaking to achieve equilibrium, 2-mL aliquots were 
withdrawn at 12-hour intervals and filtered 
immediately using a 0.45 µl nylon disc filter. The 
filtered samples were diluted suitably and assayed for 
pyrazinamide by measuring absorbance at 475 nm by 
using Shimadzu double beam UV spectrophotometer. 
Shaking was continued until 3 consecutive estimations 
were the same (96 hours). The phase solubility 
experiments were conducted in triplicate. The blanks 
were performed on the same concentrations of CDs in 
water so as to cancel any absorbance that may be 
exhibited by the CD molecules.  
 
Where So is the intrinsic solubility of rifampicin.  
Preparation of the complexes (Solid Binary 
System): Different methods were used for the 
preparation of β-CD complexes of rifampicin. The 
methods include common solvent (cosolution) and 
kneading. In case of rifampicin 1:1 molar ratio of drug 
with methylβ-CD, were prepared. The optimum ratio 
was determined by phase solubility studies. Physical 
mixtures (PM) of drugs and cyclodextrin were 
prepared in the same ratios. 
 Physical Mixture (PM): 1:1 molar ratio in case of 
rifampicin to β-CD and its derivatives was taken in 
mortar in geometrical ratio and triturated for one hour. 
The dry powder obtained was passed through the sieve 
no. 85 and stored in a desiccator.  
Kneading complex (KN):1:1 molar ratio of rifampicin 
to β-CD was taken in mortar and adequate distilled 
water was added to make paste-like consistency. The 
paste was kneaded for half an hour and dried in an 
oven at RT for one week. The obtained mass was then 
pulverized, passed through sieve no. 85 and stored in a 
desiccator. 
Common Solvent (CS): Similarly drug and complexing 
agents were dissolved in suitable solvent (chloroform 
or DMF are used in case of rifampicin). The solutions 
were mixed in ratio as mentioned in physical, and 
kneading method and evaporated to dryness at 
ambient temperature. The dry mass obtained was 
pulverized, passed through the sieve no. 85 and stored 
in a desiccator. 
Content uniformity 
The percentage of rifampicin in each of 
complexes was determined by using the complex 
containing 100 mg of the drug. The sample that is 
rifampicin after suitable dilution with pH 7.4-
phosphate buffer was determined at 475 nm by using 
Shimadzu double beam UV spectrophotometer model 
UV-1601 116. 
CHARACTERIZATION STUDIES 
β-CD complexes were investigated to establish 
formation of complex and the intactness of the drug in 
the complex by FAB mass spectrometry, FTIR, DSC, 1H-
NMR, SEM and powder x-ray diffraction methods.  
Fourier Transform Infrared (FTIR Studies) 
IR spectroscopy was carried out for the 
following a) pure drugs, b) β-CD and derivatives, c) 
complexes using Shimadzu FTIR model 8700 by taking 
KBr disc. 
Differential Scanning Calorimetry (DSC) Studies  
 Individual coils that are heated and cooled at 
the same rate heat DSC in which sample and reference 
containers are not contiguous and heated them 
separately. Platinum resistance thermometers monitor 
the temperature of the sample and reference holders 
and electronically maintain the temperature of the two 
holders constant. Differential scanning calorimetry of 
pure drug, its physical mixture of β-CD, all the 
complexes were carried out (Perkin Elmer Pyris) with a 
temperature increase of 5 o C /min. The scanning 
temperature range was from 50o C to 250oC. 
Temperature and heat flow calibration were performed 
using indium as a standard. 
Powder X-ray diffraction Studies 
X-ray diffraction study was carried out for 
pure drug, β-CD, and their complexes (Philips 
Diffractometer Model PW 17291 and Model PW 
1050/37) with a vertical goniometric using a Nickel 
filter cu k α radiation operating at 30 KW and 20 milli 
amps in the range from 5o-40o angles. The scanning 
rate was 1 o/min.  
 Proton Nuclear Magnetic Resonance (1H-NMR) 
Spectrometry: 1H-nuclear magnetic resonance (1H-
NMR) spectroscopic experiments were performed on a 
Varian 500 MHz with dual full-band channels and z-axis 
Int. J. Ayur. Pharma Research, 2015;3(8):65-76 
 IJAPR | August 2015 | Vol 3 | Issue 8   67 
gradients using a Varian. The spectra obtained were 
measured at 298 K with an operating frequency of 
499.742 MHz. The 90 o pulse width for 1 H was 10.8 at 
a transmitter power of 50. Solutions were purged prior 
to data collection under a stream of argon for 1 hour to 
reduce the amount of dissolved oxygen.  
Scanning Electron Microscopy (SEM) 
The surface morphology of pure materials, 
their treated counterparts, and all binary systems were 
examined by scanning electron microscope. The 
samples were fixed on a brass stub using double-sided 
tape and then gold coated in vacuum by a sputter 
coater. The pictures were taken at an excitation voltage 
of 20 Kv. JSM-840A Scanning Microscope, Jeol-Japan 
with JFC-1100E Ion Sputtering Device was used.  
Fast Atomic Bombard (FAB) Mass Spectra: were 
recorded on a JEOL SX 102/DA-Mass 
Spectrometer/Data system using argon/xenon (6kV, 
10mA) as the FAB gas. The accelerating voltage was 
10kV and the spectra were recorded at room 
temperature and m-nitrobenzyl was used as the matrix.  
Solubility Studies 
 The solubility of pure rifampicin and the 
complexes was determined as reported. Excess of pure 
drug or the complex was added in 25 ml conical flask 
and the mixture was shaken for 24 hours in a 
thermostatic shaker water bath (REMI Model) at RT at 
the rate of 110-120 strokes/min, till a saturated 
solution in distilled water was obtained. The sample 
was filtered using Whatman filter paper No 44. The 
filtrate was suitably diluted and the concentration of 
drug was determined spectrophotometrically. 
Bioavailability Studies 
Eighteen male New Zealand rabbits weighing 
1.5 to 2.5 kgs were used. The following formulation was 
tested (1) I.V. Injection of pure rifampicin, (2) 
rifampicin-M ethyl-β-cd inclusion complex (CS) 
suspension in 1% sodium carboxymethylcelulose, (10 
mg rifampicin/kg) in 1%, (3) rifampicin suspension in 
1% sodium carboxy methyl cellulose (low viscosity) 
given orally. 
High Performance Liquid Chromatography (HPLC): 
The liquid chromatography consisted of a Waters 6000 
A pump, a U6K injector with a 25 loop (Waters Assoc., 
Milford, MA, U.S.A.) and a variable-wavelength Hitachi 
220-S UV detector with a chart recorder (Hitachi, 
Tokyo, Japan). Analyses were performed on a reversed-
phase C 8 Column (Hibar, LiChroCart RP-8, 250 mm x 
4.6 mm I.D., Merck).  
The operating conditions for the HPLC system 
were: a mobile phase of a freshly prepared mixture of 
acetonitrile and 10 mM phosphate buffer at pH 3.5 (1:9 
v/v); flow-rate 1.5 ml/min; temperature, ambient (25 
±1o C); UV detector wavelength, 340.  
Design: The rabbits were divided into three groups of 
six rabbits (n = 6). The order of administration was 
randomly selected. All rabbits were fasted over night 
with ad libitum access to water. All rabbits received 
rifampicin solution by intravenous administration into 
marginal vein at a dose of 30 mg/kg. Rabbit’s in-group 
1 received pure rifampicin plain powder suspension in 
1% sodium carboxy methyl cellulose while rabbit’s in-
group 2 received rifampicin complex powder 
suspension in 1% sodium carboxy methyl cellulose by 
oral feeding tube at a dose of 30 mg/kg, followed by 1 
ml of deionized water. Rabbit’s in-group 3 received 
pure rifampicin intravenous injection. Blood samples 
were collected from the marginal vein at 0, 0.25, 0.5, 1, 
2, 3, 5, 7 and 24 h. Immediately the samples were 
precipitated the plasma proteins by adding methanol 
(200 µL), followed by 1 M potassium dihydrogen 
phosphate in 0.2% ascorbic acid (1mL) to adjust the pH 
to 4.2. 
Extraction of Rifampicin: To 2 ml of plasma in a 15-ml 
test-tube 0.4 ml of 10 % (v/v) aqueous acetic acid was 
added to adjust the pH to 4.2. Rifampicin was extracted 
by shaking with 7 ml of diethyl ether:dichloromethane 
(2:1 v/v) that, after centrifugation for 10 min at 2059 g, 
was transferred to a tapered test-tube and evaporated 
under nitrogen at 40o C. The residue was dissolved in 
200 µl of methanol of which 20 µl aliquot was injected 
into the HPLC column and eluted with system. The 
elute was detected at 248 nm. A simple, specific and 
sensitive high-performance liquid chromatography 
(HPLC) method was developed for the determination of 
rifampicin in human plasma. Rifampicin and sulindac 
(internal standard) are extracted from human plasma 
using a C 2 Bond Elutextraction column. A 100-µl 
volume of 0.1 M HCl is added to the plasma before 
extraction to increase the retention of the compound 
on the extraction column. Methanol (1ml) is used to 
elute the compounds and 0.5 ml of 3-mg/ml ascorbic 
acid in water is added to the final elute to reduce the 
oxidation of rifampicin. Separation is achieved by 
reversed-phase chromatography on a Zorbax Rx C 8 
column with a mobile phase composed of 0.05 M 
potassium dihydrogen phosphate-acetonitrile (55: 45, 
v/v). Detection is by ultraviolet absorbance at 340 nm. 
The retention times of rifampicin and internal standard 
are approximately 4.4 and 7.8 min, respectively. The 
assay is linear in concentration ranges of 50 to 35 000 
mg/ml. The quantitation limit is 50ng/ml. Both intra-
day and inter-day accuracy and precision data showed 
good reproducibility. 
STABILITY STUDIES  
Solid-state Stability studies: Accelerated Thermal 
Stability studies (ICH): For rifampicin the 25o C ± 2o C 
/60% RH ± 5% are used as it is stored at cool 
temperature. 
Photostability Studies: Photostability studies are 
carried out in Newtronic chamber. Studies are carried 
in UV light and tube light 1.2 million lux hours and an 
integrated near ultraviolet energy of not less than 200-
watt hours/square meter to allow direct comparisons 
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to be made between the drug substance and drug 
product. 
HPLC System: The liquid chromatography consisted of 
a Waters 6000 A pump, a U6K injector with a 25 loop 
(Waters Assoc., Milford, MA, U.S.A.) and a variable-
wavelength W 2487 UV detector. Analyses were 
performed on reversed-phase Symmetry C 18 5 µm 
W032815 4.6 x 150 mm.  
The operating conditions for the HPLC system 
were: Composition of mobile phase is methanol and 
0.015 disodium hydrogen phosphate (75+25, v/v), pH 
adjusted to 4.5 with 85% phosphoric acid. Flow rate is 
(isocratic) 1 ml/min, temperature, ambient (25 ±1o C); 
UV detector wavelength 254 nm; sensitivity scale, 0-
0.01 a.u.f.s. 
PROTOCOL OF HPLC 
Sample preparation: Suitable quantity of composite 
sample was extracted with methanol and filter. The 
filtrate was suitably diluted with MP to get 
concentrations as described under standard solution to 
establish linearity range. HPLC System: Waters LC 
systems equipped with dual piston. 510 reciprocating 
pump and 7125 Rheodyne injector with 20 µl fixed 
loop. 
Column: Novapak RP C – 18 (5 µm) column. 150 x 3.9 
mm  
Temperature: Ambient  
Chromatographic conditions: 
1. Composition of mobile phase and its pH: Methanol-
0.01 to 0.02 M disodium hydrogen phosphate (75+ 25, 
v/v) or (70+30, v/v), pH adjusted to 4.5 with 85% 
phosphoric acid.  
2. Flow rate isocratic: 1 ml/min  
3. Volume injected: 20 µl  
4. Type of detector, detector mode and wavelength: UV-
254 nm  
5. Retention time for Rifampicin- 2.91 and  
 Degradation product of Rifampicin- 5.95  
6. Linearity range: Rifampicin – 10- 100 µg/ml  
7. Recoveries (%): 97.50- 100.45 for drugs. 
RESULTS 
Rifampicin with β-cyclodextrin derivatives 
Phase Solubility 
Phase solubility studies of rifampicin with β-
CD derivatives showed that it followed A L- type of 
phase solubility (Fig. 33 and Fig 34). 41 The slope of 
the line of phase solubility is less than unity indicating 
that stoichiometry is 1:1 for drug to complexing agent. 
The apparent 1:1 stability constants of all complexes 
were calculated according the equation given below. 
 
 
 
Where So is the intrinsic solubility of rifampicin. Slope 
of the phase solubility line. 
Content Uniformity The actual drug content in each 
binary mixture was determined. The results are 
reported (Table 22). The physical mixture, kneaded 
and common solvent products showed a good 
agreement between theoretical and actual drug 
content. 
Solubility 
The aqueous solubility of rifampicin was found 
to be maximum in Mβ-CD complexes, (Table 3, Fig.2) 
while the physical mixture showed a 2.4 fold increase 
in solubility. The increase in solubility was 2 fold when 
compared to that of pure drug in case of CS complex of 
Mβ-CD. In case of β-CD complexes, CS complex showed 
2 fold increases in solubility while KN complex showed 
the least solubility, less than that of the pure drug. 
Fourier Transform Infrared Spectroscopy (FTIR 
Spectroscopy): Considerable information can be 
obtained from FTIR spectral interpretation, regarding 
the involvement of various functional groups in 
hydrogen bonding. This generally shifts the absorbance 
bands to the lower frequency increases the intensity 
and widens the band caused by stretching vibration of 
the group involved in the formation of the hydrogen 
bond. In case of FTIR of M β-CD complexes (Fig. 3), the 
stretch of >CH=N of rifampicin from 1647.1 cm -1 to 
1625.9 cm -1, the stretch of -C-H, from 2883.4 cm -1 to 
2844.8 cm -1 were shifted, and 1436.9 cm -1 of C-H was 
disappeared in the KN further confirmed the formation 
of complex with part of molecule i.e. 4-methyl 
piperazin-1-ylimino-methyl side chain was included in 
the complex. Breakage of hydrogen bond at 1023 cm -1 
frequency of secondary alcoholic group was observed 
in all the cases. But no changes were observed in case 
of PM. The reduced intensities of peaks of rifampicin 
were observed in CS complex. Thus complexation of 
rifampicin could be obtained in M β-CD complexes 
where a part of drug molecule might have included 
within the cyclodextrin molecule. 
Differential Scanning Calorimetry (DSC) 
M-β-CD Complexes 
 In DSC thermograms of M β-CD complexes 
(Fig. 4), endothermic melting peaks of pure drug at 
185.020o C and 229.110o C were reduced in area 
significantly or absent in the complexes obtained by 
different methods. New exothermic peak was observed 
at 214.230oC in kneading complex and endothermic 
peaks of rifampicin were almost disappeared, which 
indicated maximum interaction. Similarly in case of CS 
complex the endothermic peaks of rifampicin were 
absent, which indicated complete interaction. 
Powder X-ray diffraction  
X-ray diffraction reveals that the crystalline 
nature and change in the crystalline structure. There 
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were 47 peaks and 29 peaks in powder X-ray 
diffraction patterns of β-CD and pure rifampicin 
respectively that showed their crystalline nature. One 
peak at 12 o of 2 θ angles was observed in pure M β-CD 
and 12 peaks were observed in the range of 2 θ angles 
from 11 o to 27.5 o in pure rifampicin. As expected 13 
peaks is their mixture, provided there is no interaction. 
However X-ray diffraction pattern showed 4 peaks in 
the physical mixture and single peak each in the 
complexes prepared by KN and CS. 
Proton Nuclear Magnetic Resonance (1H-NMR)  
1H-NMR studies are used to investigate 
whether the type of interaction is hydrogen bond 
formation, van der Waals forces or dipole-dipole 
interaction. It also helps to interpret the geometry, 
stoichiometry and alignment of the guest molecule in 
the CDs cavity. 1H-NMR study is used to investigate the 
type of interaction. The changes in the chemical shift 
were positive (desheilding) and negative (shielding). In 
this study the changes in chemical shifts to second 
decimal were taken. The 1H-NMR studies revealed that 
changes in chemical shift of group, –CH=N of rifampicin 
molecule in the complexes are given in Table 23. 
Another group, >NH group ppm of pure rifampicin has 
been changed to second decimal (Table 24). The 1H-
NMR spectra of rifampicin, cyclodextrin complexes 
prepared by different methods are given in Fig. 6, Fig. 7, 
Fig.8 
Scanning Electron Microscopy Studies 
SEM studies reveal change in the morphology 
of particles and homogeneity of the product. Even if 
there is a clear difference in crystallization state of the 
raw material and the products, this study is inadequate 
to confirm inclusion complexation, but helps to assess 
the existence of homogeneity of single component in 
the preparations obtained. SEM observed that SEM of 
the M β-CD (Fig. 9) had shown ball shaped in pure 
compound and these ball shaped particles are 
disappeared in the complexes. Both the drug and pure 
rifampicin particles were observed in the PM. KN 
complex has shown small crystals while irregular 
shaped crystals were seen in the CS. It was observed 
that complex is single component indicating the 
interaction in KN and CS. 
Mass Spectroscopy 
Mass spectrometry of CS complex of M β-CD 
and rifampicin reveals that mass of theadduct formed 
out of complexation and also supports that the 
stoichiometry of the complexes. The FAB mass 
spectroscopy showed that adduct, with molecular 
weight 2126 +, which is sum of M β-CD, 1303 +and, 
rifampicin, 822.95 +. This supports the stoichiometry of 
rifampicin and M β-CD for the formation of complex is 
1:1. 
In vitro Anti-tubercular Activity  
The MIC for laboratory strain (H 37 RV) was 
found to be identical that is 4µg/ml for pure rifampicin 
as well as complexes of rifampicin, but, in case of wild 
strain No.10934, MIC was found to be 64µg/ml for pure 
rifampicin. However, a reduction in MIC from 64µg/ml 
to32 µg/ml was observed in all the complexes of 
rifampicin. 28 M β-CD complexes were showing no 
growth at all concentration thus exhibiting maximum 
effectiveness. 
BIOAVAILABILITY  
Plasma profiles are given the in Table 8. AUC 
IV, 0-24 of rifampicin (Fig. was found to be 90.34 ± 1.54 
hr µg/ml (Kinetica Software was used. The AUC 0-24 of 
rifampicin CS complex was 85.86 ± 2.98 hr µg/ml 
(prepared by M β-CD (common solvent) and AUC 0-24 
for pure rifampicin (oral) was 64.52 ± 3.6 hr µg/ml. 
The C max found to be 25 ± 0.73 µg/ml, 14.4± 
0.13µg/ml, and 15.7 ± 0.35 µg/mlfor IV, oral pure drug, 
and CS respectively. The T max was found to be 1.15 
hrs in case pure rifampicin and CS complex. The half-
life was found to 6.2 ± 1.2 hrs, 6.5 ± 1.3 hrs, and 6.96 ± 
1.32 hrs for IV, oral pure drug, and CS respectively. 
Stability Studies in Solution 
Thermal Stability Studies: The thermal degradation 
constant for pure rifampicin on the basis of first order 
kinetics was found out to be 8.9535 ± 0.2795 x 10 -5 
day -1, the KN complex of M β-CD showed the least 
value, 6.101 ± 0.190 x 10 -5 day -1. The reduction in 
degradation constant found to be statistically 
significant (p <0.05). 
Photostability Studies: The photostability studies 
revealed that there is no physical changes were 
observed. There is no observable colour change in 
samples. The reduction or decrease in purity for 
rifampicin and the least of all rifampicin-CD in 6 
months were observed in 6 months is 1.69%, 1.50% 
respectively. 
CONCLUSION 
Thus it can be concluded that rifampicin 
complex rifampicin could be successfully prepared by 
the kneading and common solvent methods. The 
complexes were found to have enhanced solubility, and 
dissolution rate when compared to the pure drug. FAB 
mass spectrometry, FTIR, and 1H-NMR methods 
confirmed the intactness of drug in the complexes. In 
case of rifampicin a part of rifampicin molecule i.e. 4-
methyl piperazin-1-ylimino-methyl chain was 
interacted with cyclodextrin molecules as indicated by 
FTIR and 1H-NMR. Powder x-ray diffraction, DSC and 
SEM studies confirmed the change in crystallinity of 
both drugs. The M β-CD complexes had shown 
maximum stability constant, solubility, and anti 
mycobarium activity. In case of DSC of M β-CD 
complexes, the endothermic peaks of rifampicin were 
almost disappeared. The thermal and photostability of 
rifampicin was improved significantly. Increased i n 
vitro anti-tubercular activity of the rifampicin was 
observed and it is concluded that these complexes have 
a potential of increased anti-tubercular activity. 
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Similarly the dose of rifampicin can be reduced as MIC 
was reduced. Thus inclusion complexation of 
pyrazinamide with β-CD and rifampicin with β-
cyclodextrin, β-cyclodextrin derivatives and γ-
cyclodextrin improved its physical properties, 
bioavailability and in vitro activity. 
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TABLES 
 
Table: 1 Comparison of the stability constants (K s) of complexing agents with the rifampicin 
Types of cyclodextrin Stability constant(Ka) 
By solubility method(m-1) 
 M β-CD  294.27±21.4 
Each value is an average of three determinations with SE 
Table: 2 Drug content in complexes of rifampicin (Binary Mixtures) (% molar ratio ± SE) 
Complexing agent  Methods of preparation Theoretical (%) Actual (%) 
 
 Mβ-CD 
PM  50 49.78 ± 0.18 
KN  50 48.89 ± 0.12 
 CS  50 49.70 ± 0.14 
Each value is an average of three determinations with SE 
Table: 3 Solubility of rifampicin and its complexes in water 
 S.N. Complexing agent Methods of preparation Solubility (mg/ml) 
 1 Methyl-β-cyclodextrin Physical mixture 3.200 ± 0.058 
 2 kneading 2.760 ± 0.058 
 3 Common solvent 2.960 ± 0.048 
Each value is an average of three determinations with SE 
Table 4: 1H-Chemical Shifts corresponding to CH=N group of rifampicin (δfree = 8.826) in the Presence and 
Absence of complexing agents 
Complexing agent Cmplex δcomplex Δδa 
 
 M-β-CD 
 PM  8.834  +0.008 
 KN  8.862  +0.036 
 CS  8.866  +0.040 
Table 5: 1H-Chemical Shifts corresponding to >NH group of rifampicin group (δfree = 12.533) in the presence 
and absence of complexing agents 
Complexing agent  Complex δcomplex Δδa 
 
 M-β-CD 
PM 12.529 -0.010 
KN 12.516 -0.017 
 CS 12.519  -0.014 
Table: 6 Anti-tubercular activities of rifampicin and its cyclodextrin complexes Strain: H 37 RV 
Complexing agent  Methods of 
preparation 
 Drug c.  
 1μg/ml 
 Drug c. 
 2μg/ml 
 Drug c. 
 4μg/ml 
Pure rifampicin   2+  1+  NG 
M-β-CD  KN  3+  1+  NG 
 CN  3+  5C  NG 
Note: 1+ = >100 colonies &<200 2+ = >200 colonies &<300 3+ = >300 colonies NG = No growth C = Colonies 
Table-7 Anti-tubercular activities of rifampicin and its cyclodextrin complexes Strain 10934 
Complexing agent Prepn method Drug concn 
 16µg/ml 
Drug concn 
 32μg/ml 
Drug concn 
 64μg/ml 
Pure rifampicin   1+  25C  NG 
M-β-CD  KN  20C  NG  NG 
 CS  NG  NG  NG 
Note: 1+ = >100 colonies &<200 C = Colonies NG = No growth 
Table: 8 Bioavailability rifampicin of IV, oral, and CS of M- β-CD 
S No. Time 
(hrs) 
Plasma concentration (μg/ml) 
I.V. Oral Pure drug Oral CS 
1 0 25.00±2.00 0 0 
2 0.5 18.00±1.26 5.8±0.79 7.00±0.57 
3 1 13.60±1.77 11.3±0.88 12.10±1.51 
4 1.5 10.30±0.96 14.4±0.23 15.70±0.61 
5 2 8.8±0.17 9.3±1.07 12.10±1.03 
6 3 6.6±1.51 8.6±0.99 8.60±0.44 
7 4 4.1±0.84 5.4±1.32 6.90±0.35 
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8 6 3.8±0.62 3.1±1.10 3.60±0.44 
9 8 2.4±0.62 2.2±0.30 1.98±0.18 
10 24 0.8±0.11 0.8±0.14 0.80±0.18 
*Each value is an average of three determinations with SD 
Table 9: Degradation constants complexes of rifampicin, and β-CD derivatives in aqueous solutions at 
different temperatures 
Complexing 
agent 
Methods of 
prepn 
 100oC 
 -k x 10-2 
 (Min-1) 
 450c 
 -k x 10-2 
 (Min-1) 
 RT 
 -k x 10-2 
 (Min-1) 
Pure drug  1.126±0.016 0.136±0.021 0.0005±0.00002 
 
 M-β-CD 
 PM 0.8370±0.120 0.0721±0.002 0.0004±0.00002 
 KN 0.5087±0.050 0.0858±0.001 0.0003±0.00002 
 CS 0.5409±0.061 0.0328±0.002 0.0004±0.00002 
*Each value is an average of three determinations with SE 
k = first order rate constant, 
- ve sign indicate the decrease in the value 
Table10: Accelerated stability study of rifampicin and M β-CD complex 
S.No. Time in days Concentration in mg 
R PM KN CS 
1 0 9.997±0.0058 9.997±0.0033 9.996±0.0033 9.983±0.0033 
2 30 9.975±0.0022 9.979±0.0010 9.977±0.0033 9.968±0.0017 
3 60 9.947±0.0025 9.965±0.0050 9.957±0.0033 9.950±0.000 
4 90 9.921±0.0047 9.942±0.0072 9.936±0.0033 9.931±0.0007 
5 120 9.889±0.0003 9.916±0.0088 9.924±0.0031 9.910±0.0000 
6 150 9.870±0.0058 9.892±0.0017 9.903±0.0033 9.893±0.0033 
7 180 9.841±0.0058 9.873±0.0012 9.886±0.0033 9.860±0.0058 
*Each value is an average of three determinations with SE 
Table 11: Degradation constants of rifampicin and its cyclodextrin complexes (Thermal) 
S.No. Complexing agent Methods of prepn Degredatation constant -k x 10-5 
 1  Pure drug  8.954 ± 0.280 
 2  
 M-β-CD 
 PM 7.088 ± 0.924 
 3  KN 6.101 ± 0.190 
 4  CS 7.719 ± 0.209 
*Each value is an average of three determinations with SE 
Table 12: Photo stability study of rifampicin and M β-CD complexes 
S.No. Time in days Concentration in mg 
R PM KN CS 
1 0 9.997±0.0033 9.990±0.0058 9.983±0.0033 9.985±0.0029 
2 30 9.971±0.0058 9.972±0.0061 9.963±0.0033 9.967±0.0015 
3 60 9.942±0.0015 9.960±0.0029 9.942±0.0043 9.944±0.0031 
4 90 9.917±0.0015 9.938±0.0017 9.921±0.0017 9.920±0.0006 
5 120 9.897±0.0033 9.921±0.0010 9.987±0.0033 9.908±0.0044 
6 150 9.869±0.0021 9.903±0.0017 9.875±0.0050 9.888±0.0044 
7 180 9.841±0.0067 9.891±0.0017 9.853±0.0067 9.985±0.0029 
*Each value is an average of three determinations with SE 
Table 13: Degradation constants of rifampicin and its cyclodextrin complexes in photostability studies 
S.No. Complexing agent Methods of prepn Degratation constant -K X 105 
1  Pure drug  8.734 ± 0.107 
2  
 M-β-CD 
 PM 5.646 ± 0.296 
3  KN 7.351 ± 0.327 
4  CS 0.222 ± 0.050 
*Each value is an average of three determinations with SE 
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Fig: 1 Phase solubility studies of rifampicin and M 
β-cyclodextrin. 
mcd is M –β-CD, y = 0.2216 x + 1.5573, R 2 = 1 
 
Fig: 2 Solubility of complexes of rifampicin and β-
CD derivatives in water. 
Solubility of (A) pure rifampicin, (B) Mβ-CD-rifampicin 
prepared physical mixture, (c) M β-CD-rifampicin 
prepared by kneading, (d) M β-CD-rifampicin prepared 
by common solvent method. 
 
  
Fig: 3 FTIR Spectra of rifampicin, M- β-CD and their 
inclusion complexes. 
FTIR Spectra of rifampicin (A) pure rifampicin; (B) M-
β-CD; (C) M- β-CD-rifampicin physical mixture; (D) M-
β-CD-rifampicin prepared by kneading (E) M-β-CD-
rifampicin prepared by common solvent.   
 
Fig. 4: DSC Thermograms of rifampicin, M- β-CD 
their inclusion complexes. 
DSC thermogram of (A) pure rifampicin; (B) M β-CD; 
(C) M β-CD-rifampicin physical mixture; (D) M β-CD-
rifampicin prepared by kneading; (E) M β-CD-
rifampicin prepared by common solvent method. 
 
 
Fig. 5: Powder x-ray diffraction pattern of 
rifampicin, M-β-CD and their inclusion complexes. 
Powder X-ray diffraction pattern of (A) pure 
rifampicin; (B) Mβ-CD; (C) M β-CD- rifampicin physical 
mixture; (D) M β-CD-rifampicin prepared by kneading 
and (E) M β-CD-rifampicin prepared by common 
solvent. 
  
Fig. 6: 1H-NMR spectrum of rifampicin-M- β-CD 
(PM) in DMSO (D 6) 
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 Fig. 7: 1H-NMR spectrum of rifampicin-M- β-CD 
(KN) in DMSO (D 6) 
 
 
Fig. 8: 1H-NMR spectrum of rifampicin-M-β-CD (CS) 
in DMSO (D 6) 
 
Fig 9: Scanning electron microscopy of rifampicin, M- β-CD and their inclusion complexes 
Scanning electron microscopy of rifampicin (A) pure rifampicin; (B) M β-CD; (C) M β- CD-rifampicin physical 
mixture; (D) M β-CD-rifampicin prepared by kneading and (E) Mβ-CD-rifampicin prepared by common solvent  
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Fig. 10: Mass spectrum of rifampicin-M- β-CD at 10 kV, m-nitrobenzyl was used as matrix 
 
 
Fig. 11 : Bioavailbility of rifampicin IV, its oral and CS of M - β-CD I.V. - Plasma profiles Intravenous Injection 
Pure drug oral- Plasma profiles of rifampicin Oral CS- Plasma profiles of CS complex of M β-CD 
 
